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osting by EAbstract Alloimmunisation was one of the most important causes of perinatal mortality and mor-
bidity by the middle of the last century. The objective of the present study was to investigate the
presence of the RHD gene in fetal cells (amniocytes) obtained from amniotic ﬂuid by genotyping
to compare it with the RhD serotyping. Also to correlate the presence of RhD gene with the neo-
natal outcome. This work was carried out at Maternity hospital and Medical Genetics center, while
PCR testing was done at the Medical Research center, Faculty of Medicine, Ain Shams University
in the period from 2008 to 2010. The present study included recruiting of 20 RhD negative (sensi-
tized to the RhD antigen) pregnant mothers. The entire study group was subjected to complete
general, obstetric and a detailed obstetric ultrasonographic examination. Rh typing and indirect
Coomb’s test were also done. Amniocentesis was performed with a 20-gauge needle under contin-
uous ultrasound guidance. RhD serotyping of the fetuses showed that, 14 fetuses (70%) were
positive and six fetuses (30%) were negative. While using RhD gentyping 13 cases (65%) were
positive and seven cases (35%) were negative (P value = 0.002). Among fetuses positive for
RhD genotyping six fetuses (46%) had received postnatal treatment, while among fetuses negative
for RhD genotyping, neither of them had received postnatal treatment (P value = 0.032), which is
statistically signiﬁcant. From the present study we can conclude that, the identiﬁcation of anB) El-Sewasry District, Naser
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128 SM.N. El Din et al.antigen-negative fetus on the basis of the blood group genotype provides signiﬁcant advantages in
managing the pregnancy at risk for HDFN.
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Alloimmunisation was one of the most important causes of
perinatal mortality and morbidity by the middle of the last
century. It was affecting 1–2% of all pregnancies and approx-
imately 50% of Rhesus (Rh) immunized pregnancies were lost
[1]. This was reduced by100-fold in the last decades using pro-
phylactic immunoglobulin and fetal therapy procedures, par-
ticularly an intrauterine intravascular transfusion (IUIVT)
[2]. Today the incidence of hemolytic disease of the newborn
secondary to Rh disease is approximately one to six cases
per 1000 pregnancies [3]. Despite the development and imple-
mentation of Rh(D) immune globulin prophylaxis, maternal
Rh alloimmunization is still a cause of erythroblastosis fetalis
and hemolytic disease of the newborn. However, with appro-
priate monitoring and intervention, hemolytic disease of the
fetus and newborn can be treated successfully in almost all
cases. The outcome of alloimmunized pregnancies is generally
very good, with no long-term sequelae in offspring [4].
Maternal alloimmunization, also known as isoimmuniza-
tion, occurs when a woman’s immune system is sensitized to
foreign erythrocyte surface antigens, stimulating the produc-
tion of immunoglobulin G (IgG) antibodies [5]. Antenatal
determination of fetal blood group is important in pregnancies
with a signiﬁcant risk of hemolytic anemia due to maternal
alloimmunization. Evaluation for the presence of maternal
anti-D antibody should be undertaken at the ﬁrst prenatal visit
[6]. First-time sensitized pregnancies are followed with serial
maternal titers and, when necessary, serial amniocenteses is
indicated to detect fetal bilirubin. The bilirubin level is quanti-
ﬁed by spectrophotometry and expressed as the change in
optical density at a wavelength of 450 nm (DOD450); the
DOD450 values are then plotted on a chart devised by Liley
to estimate the severity of anemia [7]. To reduce the risk of
Rh alloimmunization in a subsequent pregnancy, RhD-nega-
tive women are given anti-RhD antibodies after miscarriage,
the birth of an RhD-positive baby, or any obstetrical proce-
dure that may cause fetomaternal hemorrhage [8].
Among the more than 50 different antigens capable of caus-
ing maternal alloimmunization and fetal hemolytic disease, the
Rhesus (Rh) blood group system is the most common. The Rh
blood-group antigens are carried by a series of at least three
homologous but distinct membrane-associated proteins10 [9].
Two of these proteins have immunologically distinguishable
isoforms designated C, c and E, e. Of note, The principal
protein, D, has no immunologically detectable isoform d.
Therefore, the presence or the absence of the RhD gene in
the genome determines the genetic basis of the polymorphisms
associated with Rh positivity and Rh negativity.
The D antigen of the Rh blood group system (RhD) causes
most cases of severe hemolytic disease [10]. The incidence of fe-
tuses at risk for anemia due to maternal alloimmunization to
red cell antigens has decreased dramatically since the institution
of routine anti-D immune globulin (RhoGAM) prophylaxis for
Rh-negative women in the 1960s. A review of birth certiﬁcatedata in 2003 reported the incidence of Rh sensitization to be
approximately 6.8 per 1000 live births [11].
The prevalence of the RhD-negative blood type is depen-
dent on ethnicity with whites having the highest prevalence,
while Asians and American Indians having the lowest. Of
the existing Rh antigen, the D antigen is the most immuno-
genic. Approximately 10% of pregnancies in white women
are Rh incompatible [12]. However, because the risk of
alloimmunization in a susceptible RhD-negative woman is
signiﬁcantly affected by several factors, less than 20% of
RhD-incompatible pregnancies actually lead to maternal
alloimmunization. These factors include the volume of fetoma-
ternal hemorrhage, the degree of maternal immune response,
concurrent ABO incompatibility, and fetal homozygosity ver-
sus heterozygosity for the D antigen [13].
Two genes have been identiﬁed on the short arm of chro-
mosome 1 that encode the major Rh antigen groups (c/C, D,
e/E): RHD and RHCE, with differential protein production
in the latter is likely to be due to alternative splicing. Inheri-
tance of these so-called Rh locus genes is closely linked, thus
allowing estimations of paternal heterozygosity at the Rh D lo-
cus to be made using gene frequency tables that incorporate
data on paternal ethnicity, blood type, and number of previous
RhD-positive infants [14].
Causes of maternal alloimmunization include: Blood trans-
fusion, fetomaternal hemorrhage (antepartum, intrapartum),
abortion (therapeutic, spontaneous), ectopic pregnancy, pla-
cental abruption, abdominal trauma, obstetric procedures
(amniocentesis, chorionic villus sampling (CVS), percutaneous
umbilical blood sampling, manual removal of the placenta)
[15].
IgG antibody-mediated hemolysis of fetal erythrocytes,
known as hemolytic disease of the fetus and newborn (HDFN),
varies in severity and can have a variety of manifestations [16].
The degree of anemia can range from mild to severe with
associated hyperbilirubinemia and jaundice. In severe cases,
hemolysis may lead to extramedullary hematopoiesis and retic-
uloendothelial clearance of fetal erythrocytes. This may result
in hepatosplenomegaly; decreased liver function; and ensuing
hypoproteinemia, ascites, and anasarca. When accompanied
by high-output cardiac failure and pericardial effusion, this
condition is known as hydrops fetalis. Without intervention,
this syndrome is often fatal. Intensive neonatal care, including
emergent exchange transfusion [17].
Assessment of fetal RhD status is critical in determining
whether a pregnancy in an alloimmunized woman is at risk
for the development of hemolytic disease of the fetus and new-
born. Once a fetus is found to be at risk (i.e., RhD positive),
the goals of managing the alloimmunized pregnancy are
twofold. First is the detection of fetal anemia prior to the
occurrence of fetal compromise. After detection, the goal is
to minimize fetal morbidity and mortality by correcting this
anemia until fetal lung maturity and delivery can be achieved.
Because of the potential need for invasive diagnostic and ther-
apeutic procedures, pregnancies complicated by erythrocyte
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cine specialists [18].
In fact, Rhesus antibodies when managed by close monitor-
ing, routine antenatal anti-D prophylaxis (RAADP) and timely
delivery can lead to favorable outcome among RhD-negative
women, also it can prevent sensitisation and hence prevent
hemolytic disease of the newborn (HDN) [19].
The objective of the present study was to investigate the
presence of the RHD gene in fetal cells (amniocytes) obtained
from amniotic ﬂuid by genotyping to compare it with the RhD
serotyping. Also to correlate the presence of RhD gene with
the neonatal outcome.
2. Subjects and methods
This work was carried out at Maternity hospital and Medical
Genetics center, while PCR testing was done at the Medical
Research center, Faculty of Medicine, Ain Shams University
in the period from 2008 to 2010. The present study included
recruiting of 20 RhD negative pregnant mothers.
2.1. Subjects
Mothers eligible to be included were: RhD negative mothers
(mothers sensitized to the RhD antigen and multipara pregnant
women). The mean gestational age at which amniocentesis was
done is 26 ± 1.87 weeks, with minimum gestational age
19 weeks and maximum gestational age 32 weeks. While,
non-sensitized mothers, mothers having nonimmune hydrops
foetalis and primigravida pregnant women were excluded.
An informed consent was obtained from all the cases.
2.2. Methods
The entire study group was subjected to the following:
(1) Full detailed medical history and history suggestive of
haemolytic disease in previous pregnancies, including
miscarriages, ectopic pregnancy, stillbirths, previous
hydrops, previous intrauterine blood transfusion, early
neonatal deaths, neonatal exchange transfusion and his-
tory of maternal blood transfusion.
(2) Complete general, obstetric and a detailed obstetric ultr-
asonographic examination.
(3) Blood and biochemical tests including blood grouping,
Rh typing and indirect Coomb’s test.2.2.1. Sampling procedure
Amniocentesis was performed with a 20-gauge needle under
continuous ultrasound guidance. Since the majority of partial
D phenotype involves hybrid Rh genes; where exchange of
DNA has occurred between the RHD and RHCE genes.
RhD genotyping, if directed to these regions of exchange,
would incorrectly type some partial D phenotypes as D nega-
tive as stated by Santanu and Samia [19], therefore we studied
a speciﬁc sequence to RHD gene (exon 10). Ampliﬁcation of
DNA by polymerase chain reaction (PCR) of a unique se-
quence of the RHD gene was performed on AF after DNA
extraction. Results were compared to the neonatal RhD sero-
logical typing.The samples were transferred to the Medical Research cen-
ter (MRC) within half an hour.
In 16 cases the procedure was also performed for the man-
agement of suspected alloimmunization in RhD negative
mothers and in four cases for fetal karyotyping.
2.2.2. DNA preparation
Amniotic ﬂuid was centrifuged at 10,000·g for 10 min. The
resulting sediment cells were suspended in phosphate- buffered
saline solution. The centrifugation and washing procedures
were repeated twice. After the third centrifugation, the cell pel-
let was incubated with 400 microl of buffer containing
20 mmol/L TRIS (pH 8), 50 mmol/L potassium chloride,
1.5 mmol/L magnesium chloride, 0.5% polysorbate 20 (Tween
20) and 250 mg of proteinase K per milliliter. After incubation
at 37 C for 3 h or at 55 C for 1 h, the protease was heat inac-
tivated and a 2-microl aliquot was used for PCR ampliﬁcation.
2.2.3. Polymerase chain reaction
The RhD gene speciﬁc DNA fragments were ampliﬁed using
PCR assay.
The following primers were used:
A3 (50TAAGCAAAAGCATCCAA30) sense primer, posi-
tion 1252–1268).
A4 (50ATGGTGAGATTCTCCT30) antisense primer, posi-
tion 1437–1422).
The nucleotide sequences of the primers used were deduced
from RhIX cDNA [20] and from RhXIII cDNA (Le Van Kim)
[21].
The primer pairs amplify a 186 base-pair (bp) fragment at
exon 10, speciﬁc for the RhD gene. PCR was performed in
20-microl reaction mixtures. Thirty cycles of denaturation
for 1 min at 92 C, primer annealing for 1 min at 49 C, and
primer extension for 1 min at 72 C were performed, followed
by a ﬁnal primer extension for 9 min at 72 C. The reaction
products were separated by electrophoresis with a 3% agarose
gel containing 0.5 lg of ethidium bromide per milliliter and
were visualized under ultraviolet light.
Photographs were taken using polaroid camera. The detec-
tion of PCR products (186 bp) indicated an RhD positive fe-
tus, while the lack of the RhD-speciﬁc fragment indicated an
RhD negative status.
The turn around time of the PCR was one to two days.
2.2.4. Serologic RhD typing
The results of PCR analysis were compared with those of RhD
serotyping, which was done on fetal blood obtained by fetal
blood sampling procedures or on cord blood samples at birth.
3. Results
The results of the present study could be summarized in the
following points:
(1) RhD serotyping of the fetuses showed that, 14 fetuses
(70%) were positive and six fetuses (30%) were negative.
While using RhD gentyping 13 cases (65%) were
positive and seven cases (35%) were negative
Figure 1 Agarose gel electrophoresis analysis of PCR products
represents the RhD gene ampliﬁed from amniotic ﬂuid sample
using marker 1· (M). Samples lanes from 1 to 6: indicate positive
samples of RhD gene. Sample lane no. 7: indicate RhD negative
gene.
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correlation between RhD genotyping and RhD
serotyping.
(2) Among RhD negative fetuses, the mean value of hemo-
globin was 14.8 ± 3.9 g%, while among RhD positive
fetuses it was 10.6 ± 4.7 g%. There was a statistical dif-
ference between the two values (P value = 0.050).
(3) Among fetuses positive for genotyping; 11 fetuses (85%)
were positive for Coomb’s test and two fetuses (15%)
were negative, while among fetuses negative for geno-
typing; six fetuses (86%) were negative for Coomb’s test
and one fetus (14%) was positive (P value = 0.002) indi-
cating high signiﬁcant correlation between RhD geno-
typing and direct Coomb’s test.
(4) Among fetuses positive for RhD genotyping six fetuses
(46%) had received postnatal treatment, while among
fetuses negative for RhD genotyping, neither of them
had received postnatal treatment. (P value = 0.032)
which is statistically signiﬁcant.
(5) Among fetuses positive for RhD genotyping, seven
fetuses (54%) were admitted to neonatal intensive care
unit (NICU), four fetuses (31%) were born dead
(IUFD) and two fetuses (15%) were normal. While
among fetuses negative for RhD genotyping six fetuses
(86%) were normal; only one fetus (14%) was born
dead. (P value = 0.007) which is highly signiﬁcant.
(6) Among fetuses positive for RhD genotyping, ﬁve fetuses
(38%) had hydropic changes, while among fetuses nega-
tive for RhD genotyping, only one fetus (14%) had
hydropic changes. (P-value = 0.260) which shows no
signiﬁcant correlation.
(7) Our results revealed, no statistical signiﬁcance between
level of anti-D titer and the RhD genotyping (P value =
0.159).
4. Discussion
Red cell alloimmunization is the production of antibodies tar-
geted against red blood cells. This occurs in an individual when
they are exposed to foreign red cell antigens. There are over 400
red cell antigens that have been identiﬁed [22]. If a sensitized
pregnant woman has red cell antibodies directed against a spe-
ciﬁc antigen present on the fetal red cells, several obstetrical
complications may occur from transmission of these antibodies
across the placenta to the fetus. This may result in fetal anemai,
hyperbilirubinemia, hydrops fetalis and possibly fetal death
[23]. An RhD-negative mother is at risk of RhD alloimmuniza-
tion (sensitization) if the fetus is RhD-positive. Without
immunopropylaxis, this would occur in 12–16% of pregnancies
in RhD-negative women. The risk of alloimmunization of an
RhD-negative mother with an RhD-positive infant is 16%
overall, 2% would occur antepartum, 7% would occur by
6 months postpartum and 7% would be ‘sensibilized’. Women
who are sensibilized have anti-D antibodies produced at
undetectable levels during or after the index pregnancy, but
antibodies are identiﬁed early in a subsequent pregnancy [24].
In the present study our results showed that among 20 fe-
tuses who have been included, 13 fetuses were correctly typed
as RhD positive, six fetuses were typed as RhD negative and
one was incorrectly typed as RhD negative; in this case the fe-
tus had severe hydrops fetalis and died in utero at 28 weeks.In comparison to our results, Lighten et al. [25] published a
study on 135 RhD-negative women, who were undergoing
amniocentesis for management of suspected alloimmunization.
Genotyping was done on speciﬁc portions of the Rh D and Rh
CcEe genes by polymerase chain reaction; its results were com-
pared with the serological fetal RhD type. Thirty-six were
typed RhD negative by both techniques, and 98 fetuses were
serologically typed as RhD positive; of these, 96 were correctly
typed as RhD positive and two were incorrectly typed as RhD
negative, in one of these cases the fetus had mild Rh alloim-
mune disease and required exchange transfusion at birth. In
the second case the fetus had severe hydrops fetalis and died
in utero at 28 weeks. Deoxyribonucleic acid isolated from fetal
blood was tested with the same polymerase chain reaction
technique after delivery, and in both cases the fetus was cor-
rectly typed as RhD positive.
It has been concluded from that study that prenatal fetal
RhD typing by polymerase chain reaction with amniotic ﬂuid
cells is accurate and reliable. In sensitized pregnancies it allows
early management of Rh disease and avoids invasive proce-
dures in RhD-negative fetuses. In non-sensitized pregnancies
it avoids the use of anti-RhD immunoglobulin after invasive
procedures or during pregnancy.
Goebel et al. [26] retrospectively examined the diagnostic
accuracy of prenatal RhD blood type genotyping on amniotic
ﬂuid, using a combination of two polymerase chain reaction
(PCR) methods in daily practice and concluded that prenatal
diagnosis of the fetal RhD blood type with PCR from amniotic
ﬂuid is highly accurate and associated with a minimal sensitiv-
ity of 99.5% and a minimal speciﬁcity of 98.6%. Although no
Table 2 Shows sensitivity, speciﬁcity, positive predictive
value, negative predictive value and accuracy of RhD geno-
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nine out of 927 cases differing results between PCR and sero-
logic status were encountered (see Fig. 1).
Chan [27] had evaluated the effectiveness of a testing strat-
egy of the PCR whereby PCR was not only performed to
determine the presence/absence of the RHD gene, but also
used to assess the D gene copy number (zero, one or two
RhD genes) in family studies for at risk pregnancies. Two dis-
crepant results occurred in one family: the father carried one
normal D gene and one D gene variant where PCR was tested
to be positive using exon 4 but negative using exon 7. One of a
pair of dizygotic twins inherited this abnormal D gene and was
mildly affected by HDN. The concordance rate between RhD
genotypes from amniotic ﬂuid and RhD serotypes from cord
blood was 100%, While in our study the sensitivity of detecting
the presence or absence of RHD gene using PCR ampliﬁcation
of exon 10 region only was 92% the concordance was 95%.
However in another study Van Den Vayver and Moise [28]
studied 500 cases in which four different sets of oligonucleotide
primers were used. The sensitivity and speciﬁcity of PCR typ-
ing were 98.7% and 100%, respectively, and the positive and
negative predictive values were 100% and 96.9%, respectively
(see Tables 1 and 2).
In the present study using PCR to amplify a unique se-
quence of the RhD gene at exon 10 only showed concordance
of 95%. While in a retrospective study Pereira et al. [29] eval-
uated the efﬁcacy and accuracy of the multiplex polymerase
chain reaction (PCR) ampliﬁcation, for early detection ofTable 1 Characteristic ﬁndings of the studied fetuses.
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* <0.05 = Sig.
** <0.001 = Highly sig.fetuses at risk for hemolytic disease in the population living
in Portugal included 2030 uncultured amniotic ﬂuid samples
and 2012 blood samples from the respective RhD-negative
pregnant women were studied by multiplex PCR of intron 3/
intron 4, exon 7 and 30UTR (the 3-untranslated region). Sero-
logic RhD blood groups were determined in the cord blood,
after birth, for quality control. The results showed 99.5% con-
cordance between the molecular and serologic RhD typing.
While among the 2012 serologic RhD-negative mothers, 26
had an RhD-positive allele (1.3%).
In the present study, it was found that RHD genotyping by
PCR is a valuable method of antenatal detection of RhD typ-
ing in Rh alloimmunised pregnancies with sensitiv-+ve Total P-value
% No. % No. %
35 13 65 20 100
.8 ± 3.9 10.6 ± 4.7 0.050*
86 2 15 8 40 0.002**
14 11 85 12 60
100 7 54 14 70 0.032*
0 6 46 6 30
86 2 15 8 40 0.007**
0 7 54 7 35
14 4 31 5 25
86 8 62 14 70 1.266
14 5 38 6 30
30 0 0 6 30 0.002**
5 13 65 14 70
29 0 0 2 10
14 5 38 6 30
14 4 31 5 25 0.159
29 1 8 3 15
14 3 23 4 20
132 SM.N. El Din et al.ity = 92.9%, speciﬁcity = 100% and positive predictive value
of 100% and negative predictive value of 85.7%. The diagnos-
tic accuracy of the PCR genotyping is 95%. Contrasting re-
sults were obtained by Johnson et al. [30] for the exon 10
PCR. The sensitivity was higher, 94%, but the speciﬁcity was
low, 36%.
The concordance rate between RhD genotypes from amni-
otic ﬂuid and Rh D serotypes from cord blood was 95%. There
were a highly signiﬁcant correlation between the RhD geno-
typing and RhD phenotyping.
Fetal problems from Rh sensitization are detected with
Doppler ultrasound testing and sometimes with amniocentesis.
In response to an Rh-positive fetus, immune system may
quickly develop IgG antibodies, which can cross the placenta
and destroy fetal red blood cells. Each subsequent pregnancy
with an Rh-positive fetus may produce more serious problems
for the fetus. The resulting fetal disease (called Rh disease,
hemolytic disease of the newborn, or erythroblastosis fetalis)
can be mild to severe. Mild Rh disease involves limited
destruction of fetal red blood cells, possibly resulting in mild
fetal anemia [31]. The fetus can usually be carried to term
and requires no special treatment. Moderate Rh disease in-
volves the destruction of larger numbers of fetal red blood
cells. The fetus may develop an enlarged liver and may become
moderately anemic. The fetus may need to be delivered before
term and may require a blood transfusion before (while in the
uterus) or after birth. Severe Rh disease (fetal hydrops) in-
volves widespread destruction of fetal red blood cells. The fe-
tus develops severe anemia, liver and spleen enlargement,
increased bilirubin levels, and ﬂuid retention (edema). The fe-
tus may need one or more blood transfusions before birth. A
fetus with severe Rh disease who survives the pregnancy may
need a blood exchange [32].
The present study demonstrated that fetal anemia was de-
tected among RhD positive fetuses (the mean value of hemo-
globin was 10.6 ± 4.7 g%). As regards neonatal condition,
seven RhD positive fetuses were admitted to NICU, four were
born dead (IUFD), six fetuses had received postnatal treat-
ment (phototherapy and exchange transfusion) and ﬁve fetuses
had hydropic changes in ultrasound scan. All previous results
implicate the correlation between the presence of RhD gene
and the neonatal outcome. Our ﬁndings were in agreement
with available data from Iran and other populations [33–35].
Also closely similar results were reported by Helen et al. [36].
A theoretical model indicated that amniocentesis with PCR-
based techniques for fetal RhD typing would be associated
with a fourfold reduction in perinatal loss compared with cor-
docentesis and serology for fetal typing.
The treatment of RhD alloimmunised pregnancies requires
early and safe diagnosis of the fetal RhD type. The identiﬁca-
tion of an antigen-negative fetus on the basis of the blood
group genotype provides signiﬁcant advantages in managing
the pregnancy at risk for HDFN.5. Summary and conclusion
From the present study we can conclude that different options
for management of Rhesus factor and D antigen (RhD) have
been evolved alongside the technologic advances. The ability
to determine the Rh status of the fetus early in pregnancy
without invading the fetomaternal circulation and the use ofmolecular biology techniques represents a major breakthrough
in the clinical management of RhD alloimmunization.
6. Recommendations
 Routine screening should be done at the ﬁrst prenatal visit
to determine blood group, Rh status, and the presence of
maternal antibodies.
 Use of different sets of gene speciﬁc primers at two different
loci to improve the prediction of the genotype and to elim-
inate the possibility of genetic and laboratory sources of
errors.
 Hydrops foetalis is a challenging entity for both the obste-
trician and the neonatologist. Early diagnosis and treatment
greatly improves perinatal outcome.Conﬂict of interest
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